Cargando…

Risk Factors Influencing Seroconversion after Inactive SARS-CoV-2 Vaccination in People Living with Obesity

INTRODUCTION: The aim of this study was to investigate the antibody titers against SARS-CoV-2 spike antigens and the risk factors affecting antibody levels in people living with obesity (PwO) after inactive SARS-CoV-2 vaccine (CoronaVac) administration. METHODS: 169 consecutive patients with obesity...

Descripción completa

Detalles Bibliográficos
Autores principales: Kara, Zehra, Akçin, Rüveyda, Demir, Ahmet Numan, Dinç, Harika Öykü, Kocazeybek, Bekir, Yumuk, Volkan Demirhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669952/
https://www.ncbi.nlm.nih.gov/pubmed/35921804
http://dx.doi.org/10.1159/000525555
_version_ 1784832236043894784
author Kara, Zehra
Akçin, Rüveyda
Demir, Ahmet Numan
Dinç, Harika Öykü
Kocazeybek, Bekir
Yumuk, Volkan Demirhan
author_facet Kara, Zehra
Akçin, Rüveyda
Demir, Ahmet Numan
Dinç, Harika Öykü
Kocazeybek, Bekir
Yumuk, Volkan Demirhan
author_sort Kara, Zehra
collection PubMed
description INTRODUCTION: The aim of this study was to investigate the antibody titers against SARS-CoV-2 spike antigens and the risk factors affecting antibody levels in people living with obesity (PwO) after inactive SARS-CoV-2 vaccine (CoronaVac) administration. METHODS: 169 consecutive patients with obesity who visited the Center for Obesity Management at Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty Hospitals, between May and August 2021, were invited to the study. The nonobese control group was recruited from 191 subjects who visited the Cerrahpaşa Hospitals Vaccination Unit. The study group and the nonobese control group have already received two doses of inactive SARS-CoV-2 vaccine. The SARS-CoV-2 IgG nucleocapsid antibody test was administered to patients and control subjects to discover those who had prior SARS-CoV-2 infection. Forty-one patients who had prior infection and received two doses of vaccine were also included in the study as a subgroup. Blood samples were taken on the 3rd to 4th week after the second vaccination. SARS-CoV-2 IgG antibody titers were determined by quantitative serological methods. RESULTS: Antibody titers against SARS-CoV-2 spike antigen of individuals with BMI ≥30.0 kg/m<sup>2</sup> were significantly lower than those with BMI <30 kg/m<sup>2</sup> (p = 0.001) in the study group. Moreover, the antibody titers in people with BMI ≥30.0 kg/m<sup>2</sup> were significantly lower than in those having a BMI <30.0 kg/m<sup>2</sup> in the subgroup (p = 0.03). Age (p = 0.03), BMI (p = 0.006), and hypertension (p = 0.03) were found to be independent risk factors for antibody response in PwO. Women with non-prior SARS-CoV-2 infection showed a significantly higher antibody response then men (p = 0.001). CONCLUSION: SARS-CoV-2-Immunoglobulin G antibody levels against inactive (CoronaVac) vaccine were found to be lower in PwO compared to nonobese individuals. Antibody titers may be measured, and booster doses should be delivered accordingly in PwO for optimal protection.
format Online
Article
Text
id pubmed-9669952
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-96699522022-11-18 Risk Factors Influencing Seroconversion after Inactive SARS-CoV-2 Vaccination in People Living with Obesity Kara, Zehra Akçin, Rüveyda Demir, Ahmet Numan Dinç, Harika Öykü Kocazeybek, Bekir Yumuk, Volkan Demirhan Obes Facts Research Article INTRODUCTION: The aim of this study was to investigate the antibody titers against SARS-CoV-2 spike antigens and the risk factors affecting antibody levels in people living with obesity (PwO) after inactive SARS-CoV-2 vaccine (CoronaVac) administration. METHODS: 169 consecutive patients with obesity who visited the Center for Obesity Management at Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty Hospitals, between May and August 2021, were invited to the study. The nonobese control group was recruited from 191 subjects who visited the Cerrahpaşa Hospitals Vaccination Unit. The study group and the nonobese control group have already received two doses of inactive SARS-CoV-2 vaccine. The SARS-CoV-2 IgG nucleocapsid antibody test was administered to patients and control subjects to discover those who had prior SARS-CoV-2 infection. Forty-one patients who had prior infection and received two doses of vaccine were also included in the study as a subgroup. Blood samples were taken on the 3rd to 4th week after the second vaccination. SARS-CoV-2 IgG antibody titers were determined by quantitative serological methods. RESULTS: Antibody titers against SARS-CoV-2 spike antigen of individuals with BMI ≥30.0 kg/m<sup>2</sup> were significantly lower than those with BMI <30 kg/m<sup>2</sup> (p = 0.001) in the study group. Moreover, the antibody titers in people with BMI ≥30.0 kg/m<sup>2</sup> were significantly lower than in those having a BMI <30.0 kg/m<sup>2</sup> in the subgroup (p = 0.03). Age (p = 0.03), BMI (p = 0.006), and hypertension (p = 0.03) were found to be independent risk factors for antibody response in PwO. Women with non-prior SARS-CoV-2 infection showed a significantly higher antibody response then men (p = 0.001). CONCLUSION: SARS-CoV-2-Immunoglobulin G antibody levels against inactive (CoronaVac) vaccine were found to be lower in PwO compared to nonobese individuals. Antibody titers may be measured, and booster doses should be delivered accordingly in PwO for optimal protection. S. Karger AG 2022-08-03 /pmc/articles/PMC9669952/ /pubmed/35921804 http://dx.doi.org/10.1159/000525555 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
spellingShingle Research Article
Kara, Zehra
Akçin, Rüveyda
Demir, Ahmet Numan
Dinç, Harika Öykü
Kocazeybek, Bekir
Yumuk, Volkan Demirhan
Risk Factors Influencing Seroconversion after Inactive SARS-CoV-2 Vaccination in People Living with Obesity
title Risk Factors Influencing Seroconversion after Inactive SARS-CoV-2 Vaccination in People Living with Obesity
title_full Risk Factors Influencing Seroconversion after Inactive SARS-CoV-2 Vaccination in People Living with Obesity
title_fullStr Risk Factors Influencing Seroconversion after Inactive SARS-CoV-2 Vaccination in People Living with Obesity
title_full_unstemmed Risk Factors Influencing Seroconversion after Inactive SARS-CoV-2 Vaccination in People Living with Obesity
title_short Risk Factors Influencing Seroconversion after Inactive SARS-CoV-2 Vaccination in People Living with Obesity
title_sort risk factors influencing seroconversion after inactive sars-cov-2 vaccination in people living with obesity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669952/
https://www.ncbi.nlm.nih.gov/pubmed/35921804
http://dx.doi.org/10.1159/000525555
work_keys_str_mv AT karazehra riskfactorsinfluencingseroconversionafterinactivesarscov2vaccinationinpeoplelivingwithobesity
AT akcinruveyda riskfactorsinfluencingseroconversionafterinactivesarscov2vaccinationinpeoplelivingwithobesity
AT demirahmetnuman riskfactorsinfluencingseroconversionafterinactivesarscov2vaccinationinpeoplelivingwithobesity
AT dincharikaoyku riskfactorsinfluencingseroconversionafterinactivesarscov2vaccinationinpeoplelivingwithobesity
AT kocazeybekbekir riskfactorsinfluencingseroconversionafterinactivesarscov2vaccinationinpeoplelivingwithobesity
AT yumukvolkandemirhan riskfactorsinfluencingseroconversionafterinactivesarscov2vaccinationinpeoplelivingwithobesity